European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization

@article{Hbel2012EuropeanDO,
  title={European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization},
  author={Kai H{\"u}bel and Maximilian M Fresen and J. F. Apperley and Grzegorz Wladyslaw Basak and Kenneth W Douglas and Ian H Gabriel and Catarina Geraldes and Ozren Jak{\vs}i{\'c} and Zdeněk Koř{\'i}stek and Nicolaus Kr{\"o}ger and Francesco Lanza and R. M. Lemoli and Gabor Mikala and Dominik L D Selleslag and N Worel and Mohamad Mohty and R. Duarte},
  journal={Bone Marrow Transplantation},
  year={2012},
  volume={47},
  pages={1046-1050}
}
The effectiveness of the novel hematopoietic stem cell mobilizing agent plerixafor was evaluated in nationwide compassionate use programs in 13 European countries. A total of 580 poor mobilizers with non-Hodgkin's lymphoma (NHL), Hodgkin's lymphoma (HL) and multiple myeloma (MM) were enrolled. All patients received plerixafor plus granulocyte CSF with or without chemotherapy. Overall, the collection yield was significantly higher in MM patients (>2.0 × 106 CD34+ cells/kg: 81.6%; >5.0 × 106 CD34… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 23 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 23 references

Similar Papers

Loading similar papers…